Phase 3
Prostate Cancer Clinical Trial
Recruiting
Recruiting
Recruiting
Recruiting
Estimated trial completion date
CLARIFY Trial
The CLARIFY trial studies a new PET imaging agent, 64Cu-SAR-bisPSMA, to improve prostate cancer detection before surgery. High-risk patients receive two PET/CT scans: one at 1 hour and another at 24 hours post-injection. The goal is to enhance accuracy in detecting cancer spread, aiding surgical planning.
Patients are eligible if they are/have:
- At least 18 years of age.
- Signed informed consent.
- Untreated, histologically confirmed adenocarcinoma of the prostate.
- High-risk or greater PC defined by National Comprehensive Cancer Network Guidelines Version 1.202327 (clinical stage ≥T3a, or Grade Group ≥4, or PSA >20 ng/mL).
- Patients electing to undergo RP with PLND.